These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15366746)

  • 1. Cost-effectiveness of two follow-up strategies for curative resection of colorectal cancer: comparative study using a Markov model.
    Borie F; Combescure C; Daurès JP; Trétarre B; Millat B
    World J Surg; 2004 Jun; 28(6):563-9. PubMed ID: 15366746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost and effectiveness of follow-up examinations in patients with colorectal cancer resected for cure in a French population-based study.
    Borie F; Daurès JP; Millat B; Trétarre B
    J Gastrointest Surg; 2004; 8(5):552-8. PubMed ID: 15239990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis in colorectal cancer using a semi-Markov model.
    Castelli C; Combescure C; Foucher Y; Daures JP
    Stat Med; 2007 Dec; 26(30):5557-71. PubMed ID: 18058847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health and Economic Impact of Intensive Surveillance for Distant Recurrence After Curative Treatment of Colon Cancer: A Mathematical Modeling Study.
    Wanis KN; Maleyeff L; Van Koughnett JAM; H D Colquhoun P; Ott M; Leslie K; Hernandez-Alejandro R; Kim JJ
    Dis Colon Rectum; 2019 Jul; 62(7):872-881. PubMed ID: 31188189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic follow-up after curative surgery for colorectal cancer in Norway: a population-based audit of effectiveness, costs, and compliance.
    Körner H; Söreide K; Stokkeland PJ; Söreide JA
    J Gastrointest Surg; 2005 Mar; 9(3):320-8. PubMed ID: 15749591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of surveillance intervals after curative resection of colorectal cancer.
    Takayama Y; Tsukamoto S; Kudose Y; Takamizawa Y; Moritani K; Esaki M; Kanemitsu Y; Igarashi A
    Jpn J Clin Oncol; 2024 Jun; 54(6):637-646. PubMed ID: 38376792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation. A Markov analysis.
    Kievit J; van de Velde CJ
    Cancer; 1990 Jun; 65(11):2580-7. PubMed ID: 2337875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States.
    Cho SK; Hay JW; Barzi A
    Clin Colorectal Cancer; 2018 Dec; 17(4):e751-e761. PubMed ID: 30228027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer.
    Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Harvey RD; El-Rayes BF; Flowers CR
    Clin Colorectal Cancer; 2014 Dec; 13(4):219-25. PubMed ID: 25306485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carcinoembryonic antigen for the detection of recurrent disease following curative resection of colorectal cancer.
    Wichmann MW; Lau-Werner U; Müller C; Hornung HM; Stieber P; Schildberg FW;
    Anticancer Res; 2000; 20(6D):4953-5. PubMed ID: 11326645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases.
    Ercolani G; Cucchetti A; Cescon M; Peri E; Brandi G; Del Gaudio M; Ravaioli M; Zanello M; Pinna AD
    Eur J Cancer; 2011 Oct; 47(15):2291-8. PubMed ID: 21652204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection.
    Gazelle GS; McMahon PM; Beinfeld MT; Halpern EF; Weinstein MC
    Radiology; 2004 Dec; 233(3):729-39. PubMed ID: 15564408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Follow-up of patients with colorectal cancer resected for cure in the Herault area. A medico-economical study].
    Borie F; Daurès JP; Millat B; Folschveiller-Bruggeman M; Trétarre B
    Gastroenterol Clin Biol; 2001 Oct; 25(10):881-4. PubMed ID: 11852391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performing Gadoxetic Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Suh CH; Kim KW; Park SH; Kim SY; Woo DC; Shin S; Pyo J; Shinagare AB; Ramaiya NH; Lim YS
    AJR Am J Roentgenol; 2018 Feb; 210(2):W63-W69. PubMed ID: 29091004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada.
    Hedden L; Kennecke H; Villa D; Johnston K; Speers C; Kovacic L; Renouf DJ; Peacock S
    Eur J Cancer; 2012 Sep; 48(13):1969-76. PubMed ID: 22325838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of postoperative surveillance after radical surgery for colorectal cancer: results of a cohort study.
    Castells A; Bessa X; Daniels M; Ascaso C; Lacy AM; García-Valdecasas JC; Gargallo L; Novell F; Astudillo E; Filella X; Piqué JM
    Dis Colon Rectum; 1998 Jun; 41(6):714-23; discussion 723-4. PubMed ID: 9645739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy.
    Matasar MJ; Sundararajan V; Grann VR; Neugut AI
    Drugs Aging; 2004; 21(2):113-33. PubMed ID: 14960128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
    Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
    Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of a carcinoembryonic antigen (CEA) based follow-up programme for colorectal cancer (the CEA Watch trial).
    Verberne CJ; Wiggers T; Grossmann I; de Bock GH; Vermeulen KM
    Colorectal Dis; 2016 Mar; 18(3):O91-6. PubMed ID: 26757353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.